The culinary-medicinal mushroom Coprinus comatus as a natural antiandrogenic modulator

Integrative Cancer Therapies

Volumn 10, Issue 2, 2011, Pages 148-159

  Dotan, Nesly ^a,b   Wasser, Solomon P ^b   Mahajna, Jamal ^a,c  

^a MIGAL GALILEE TECHNOLOGY CENTER   (Israel)

^b UNIVERSITY OF HAIFA   (Israel)

^c TEL HAI COLLEGE   (Israel)

Author keywords

androgen receptor; Coprinus comatus; higher basidiomycetes; LNCaP; prostate cancer

Indexed keywords

ACETIC ACID ETHYL ESTER; ALCOHOL; ANDROGEN RECEPTOR; ANTIANDROGEN; CC 734 H; CHLOROFORM; COPRINUS COMATUS EXTRACT; FUNGAL EXTRACT; HEXANE; PROSTATE SPECIFIC ANTIGEN; SELECTIVE ANDROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; COPRINUS; COPRINUS COMATUS; FUNGAL STRAIN; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALE; MEDICINAL PLANT; MITOSIS INHIBITION; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR BLOCKING;

ACTIVE TRANSPORT, CELL NUCLEUS; ANDROGEN ANTAGONISTS; ANDROGENS; ANILINE COMPOUNDS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COPRINUS; DEXAMETHASONE; DIHYDROTESTOSTERONE; DOWN-REGULATION; FEMALE; FLUTAMIDE; GENE EXPRESSION; GENES, REPORTER; HUMANS; INHIBITORY CONCENTRATION 50; LUCIFERASES; MALE; MIFEPRISTONE; NITRILES; PLANT EXTRACTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUINOLINES; RECEPTORS, ANDROGEN; RECEPTORS, GLUCOCORTICOID; TUMOR STEM CELL ASSAY; UP-REGULATION;

EID: 79959804488     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735410383169     Document Type: Article

References (47)

1. Baillargeon J, Rose DP. Obesity, adipokines, and prostate cancer (review). Int J Oncol. 2006;28:737-745.
2. Long RM, Morrissey C, Fitzpatrick JM, Watson RW. Prostate epithelial cell differentiation and its relevance to the understanding of prostate cancer therapies. Clin Sci (Lond). 2005;108:1-11. (Pubitemid 40052280)
3. Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem. 1994;63:25-61.
4. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell. 1995;83:835-839.
5. Shand RL, Gelmann EP. Molecular biology of prostate-cancer pathogenesis. Curr Opin Urol. 2006;16:123-131. (Pubitemid 43791779)
6. Trapman J, Brinkmann AO. The androgen receptor in prostate cancer. Pathol Res Pract. 1996;192:752-760. (Pubitemid 26302249)
7. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol. 2002;20:3001-3015. (Pubitemid 34728896)
8. Gnanapragasam VJ, Robson CN, Leung HY, Neal DE. Androgen receptor signaling in the prostate. BJU Int. 2000;86:1001-1013.
9. Papaioannou M, Schleich S, Prade I, et al. The natural compound atraric acid is an antagonist of the human androgen receptor inhibiting cellular invasiveness and prostate cancer cell growth. J Cell Mol Med. 2009;13:2210-2223.
10. Isaacs JT. Role of androgens in prostatic cancer. Vitam Horm. 1994;49:433-502.
11. Lara PN Jr, Twardowski P, Quinn DI. Angiogenesis-targeted therapies in prostate cancer. Clin Prostate Cancer. 2004;3: 165-173. (Pubitemid 40051708)
12. Scher HI, Chung LW. Bone metastases: improving the therapeutic index. Semin Oncol. 1994;21:630-656. (Pubitemid 24329140)
13. Balk SP. Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002;60:132-138; discussion 138-139.
14. Taplin ME. Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol. 2007;4:236-244.
15. Tindall DJ. Pursuing the androgen pathway on the quest to control prostate cancer. Cancer Biol Ther. 2007;6:805-810. (Pubitemid 47328366)
16. Lin HK, Wang L, Hu YC, et al. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J. 2002;21:4037-4048. (Pubitemid 34857436)
17. Deocampo ND, Huang H, Tindall DJ. The role of PTEN in the progression and survival of prostate cancer. Minerva Endocrinol. 2003;28:145-153.
18. Fahy BN, Schlieman MG, Mortenson MM, et al. Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmacol. 2005;56:46-54. (Pubitemid 41201755)
19. Lin Y, Martin J, Gruendler C, et al. A novel link between the proteasome pathway and the signal transduction pathway of the bone morphogenetic proteins (BMPs). BMC Cell Biol. 2002;3:15.
20. Wasser SP. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol. 2002;60:258-274.
21. Halpern MG, Miller AH. Medicinal Mushrooms: Ancient Remedies for Modern Ailments. New York, NY: Evans; 2002.
22. Cho Y, Jang YY, Han ES, Lee CS. The inhibitory effect of ambroxol on hypochlorous acid-induced tissue damage and respiratory burst of phagocytic cells. Eur J Pharmacol. 1999;383:83-91. (Pubitemid 29509826)
23. Kidd PM. The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev. 2000;5:4-27. (Pubitemid 30132069)
24. Wasser SP, Weis AL. Therapeutic effects of substances occurring in higher basidiomycetes mushrooms: a modern perspective. Crit Rev Immunol. 1999;19:65-96. (Pubitemid 29062102)
25. Zaidman BZ, Yassin M, Mahajna J, Wasser SP. Medicinal mushroom modulators of molecular targets as cancer therapeutics. Appl Microbiol Biotechnol. 2005;67:453-468. (Pubitemid 40909591)
26. Zaidman BZ, Wasser SP, Nevo E, Mahajna J. Coprinus comatus and Ganoderma lucidum interfere with androgen receptor function in LNCaP prostate cancer cells. Mol Biol Rep. 2008;35:107-117. (Pubitemid 351713238)
27. Yassin M, Wasser SP, Mahajna J. Substances from the medicinal mushroom Daedalea gibbosa inhibit kinase activity of native and T315I mutated Bcr-Abl. Int J Oncol. 2008;32:1197-1204.
28. Hartig PC, Bobseine KL, Britt BH, et al. Development of two androgen receptor assays using adenoviral transduction of MMTV-luc reporter and/or hAR for endocrine screening. Toxicol Sci. 2002;66:82-90. (Pubitemid 34202031)
29. Wilson VS, Bobseine K, Lambright CR, Gray LE Jr. A novel cell line, MDA-kb2, that stably expresses an androgen- and glucocorticoid-responsive reporter for the detection of hormone receptor agonists and antagonists. Toxicol Sci. 2002;66:69-81. (Pubitemid 34202030)
30. Woodhouse BC, Dianov GL. Poly ADP-ribose polymerase-1: an international molecular of mystery. DNA Repair (Amst). 2008;7:1077-1086.
31. Meimaridou E, Gooljar SB, Chapple JP. From hatching to dispatching: the multiple cellular roles of the Hsp70 molecular chaperone machinery. J Mol Endocrinol. 2009;42:1-9.
32. Kimura S, Ashihara E, Maekawa T. New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Curr Pharm Biotechnol. 2006;7:371-379. (Pubitemid 44524418)
33. Small EJ, Roach M III. Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response. Semin Oncol. 2002;29:264-273. (Pubitemid 34620443)
34. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1:34-45. (Pubitemid 33741879)
35. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 2003;3:768-780.
36. Scifo C, Cardile V, Russo A, et al. Resveratrol and propolis as necrosis or apoptosis inducers in human prostate carcinoma cells. Oncol Res. 2004;14:415-426. (Pubitemid 39304309)
37. Mohanty NK, Saxena S, Singh UP, et al. Lycopene as a chemopreventive agent in the treatment of high-grade prostate intraepithelial neoplasia. Urol Oncol. 2005;23:383-385. (Pubitemid 41654502)
38. Zaidman BZ, Wasser SP, Nevo E, Mahajna J. Androgen receptor-dependent and -independent mechanisms mediate Ganoderma lucidum activities in LNCaP prostate cancer cells. Int J Oncol. 2007;31:959-967.
39. Balk SP, Knudsen KE. AR, the cell cycle, and prostate cancer. Nucl Recept Signal. 2008;6:e001.
40. Brooke GN, Bevan CL. The role of androgen receptor mutations in prostate cancer progression. Curr Genomics. 2009;10:18-25.
41. Chatterjee B. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Mol Cell Biochem. 2003;253:89-101. (Pubitemid 37321715)
42. Kemppainen JA, Wilson EM. Agonist and antagonist activities of hydroxyflutamide and Casodex relate to androgen receptor stabilization. Urology. 1996;48:157-163. (Pubitemid 26255982)
43. Farla P, Hersmus R, Trapman J, Houtsmuller AB. Antiandrogens prevent stable DNA-binding of the androgen receptor. J Cell Sci. 2005;118:4187-4198. (Pubitemid 41488956)
44. Masiello D, Cheng S, Bubley GJ, et al. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem. 2002; 277:26321-26326. (Pubitemid 34967123)
45. Wang Y, Shao C, Shi CH, et al. Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism. Asian J Androl. 2005;7:375-380. (Pubitemid 41819351)
46. Urushibara M, Ishioka J, Hyochi N, et al. Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors. Prostate. 2007;67:799-807. (Pubitemid 46828934)
47. Bindukumar B, Schwartz SA, Nair MP, et al. Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth. Neoplasia. 2005;7:544. (Pubitemid 40791873)